- Home
- ULY vs INM Comparison
ULY vs INM Comparison
Compare ULY & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULY
- INM
- Stock Information
- Founded
- ULY 2013
- INM 1981
- Country
- ULY United States
- INM Canada
- Employees
- ULY N/A
- INM N/A
- Industry
- ULY
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- ULY
- INM Health Care
- Exchange
- ULY Nasdaq
- INM Nasdaq
- Market Cap
- ULY 5.8M
- INM 5.0M
- IPO Year
- ULY N/A
- INM N/A
- Fundamental
- Price
- ULY $2.53
- INM $1.73
- Analyst Decision
- ULY Strong Buy
- INM
- Analyst Count
- ULY 2
- INM 0
- Target Price
- ULY $11.50
- INM N/A
- AVG Volume (30 Days)
- ULY 87.1K
- INM 98.7K
- Earning Date
- ULY 11-12-2025
- INM 11-13-2025
- Dividend Yield
- ULY N/A
- INM N/A
- EPS Growth
- ULY N/A
- INM N/A
- EPS
- ULY N/A
- INM N/A
- Revenue
- ULY $131,235,000.00
- INM $4,942,633.00
- Revenue This Year
- ULY N/A
- INM N/A
- Revenue Next Year
- ULY $20.23
- INM N/A
- P/E Ratio
- ULY N/A
- INM N/A
- Revenue Growth
- ULY N/A
- INM 7.50
- 52 Week Low
- ULY $2.41
- INM $1.71
- 52 Week High
- ULY $17.99
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- ULY 32.15
- INM 28.07
- Support Level
- ULY $2.64
- INM $1.80
- Resistance Level
- ULY $3.07
- INM $1.92
- Average True Range (ATR)
- ULY 0.23
- INM 0.11
- MACD
- ULY 0.00
- INM -0.03
- Stochastic Oscillator
- ULY 13.41
- INM 10.09
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.